The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F24%3A10465851" target="_blank" >RIV/00216208:11160/24:10465851 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11150/24:10465851 RIV/00179906:_____/24:10465851
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QwTIe~n7CY" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QwTIe~n7CY</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10557-023-07455-y" target="_blank" >10.1007/s10557-023-07455-y</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia
Popis výsledku v původním jazyce
Patients suffering from familial hypercholesterolemia (FH) have a high risk of thrombotic cardiovascular events. The aim of the study was to analyse the impact of different therapies including convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9ab) on platelet aggregation in FH. PCSK9ab have been administered in 12 of 15 patients while 8 patients were also undergoing lipid apheresis. Blood samples from all patients including pre- and post-apheresis period were tested for platelet aggregation triggered by 7 inducers, and the effect of 3 clinically used drugs (acetylsalicylic acid, ticagrelor and vorapaxar) was compared as well. Although apheresis decreased the reactivity of platelets in general, platelet responses were not different between non-apheresis patients treated with PCSK9ab and apheresis patients (post-apheresis values) with the exception of ristocetin. However, when compared to age-matched healthy population, FH patients had significantly lower platelet aggregation responses to 4 out of 7 used inducers and higher profit from 2 out of 3 used antiplatelet drugs even after exclusion of FH patients regularly receiving conventional antiplatelet treatment.
Název v anglickém jazyce
The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia
Popis výsledku anglicky
Patients suffering from familial hypercholesterolemia (FH) have a high risk of thrombotic cardiovascular events. The aim of the study was to analyse the impact of different therapies including convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9ab) on platelet aggregation in FH. PCSK9ab have been administered in 12 of 15 patients while 8 patients were also undergoing lipid apheresis. Blood samples from all patients including pre- and post-apheresis period were tested for platelet aggregation triggered by 7 inducers, and the effect of 3 clinically used drugs (acetylsalicylic acid, ticagrelor and vorapaxar) was compared as well. Although apheresis decreased the reactivity of platelets in general, platelet responses were not different between non-apheresis patients treated with PCSK9ab and apheresis patients (post-apheresis values) with the exception of ristocetin. However, when compared to age-matched healthy population, FH patients had significantly lower platelet aggregation responses to 4 out of 7 used inducers and higher profit from 2 out of 3 used antiplatelet drugs even after exclusion of FH patients regularly receiving conventional antiplatelet treatment.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
<a href="/cs/project/NU21J-02-00021" target="_blank" >NU21J-02-00021: Rozdíly v parametrech agregace krevních destiček a koagulace krve mezi zdravými osobami a pacienty s metabolickými chorobami</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Cardiovascular Drugs and Therapy
ISSN
0920-3206
e-ISSN
1573-7241
Svazek periodika
38
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
12
Strana od-do
959-970
Kód UT WoS článku
000980357300001
EID výsledku v databázi Scopus
2-s2.0-85156105870